Published in Am J Physiol on January 01, 1993
Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol (2008) 2.04
Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci U S A (2003) 1.56
Natriuretic peptides and therapeutic applications. Heart Fail Rev (2007) 1.44
Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci U S A (2006) 1.18
Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem (2008) 1.16
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail (2013) 1.02
Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol (2009) 1.02
Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest (1993) 0.97
Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure. Gut (2000) 0.88
Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb Exp Pharmacol (2009) 0.88
Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. Circ Res (2013) 0.84
Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors. Mol Pharmacol (2010) 0.82
C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade. Life Sci (2011) 0.79
Vascular relaxation induced by C-type natriuretic peptide involves the ca2+/NO-synthase/NO pathway. PLoS One (2014) 0.79
In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. PLoS One (2013) 0.78
Direct chronotropic effects of atrial and C-type natriuretic peptides in anaesthetized dogs. Br J Pharmacol (1996) 0.78
Designer natriuretic peptides. J Investig Med (2009) 0.77
Neuroendocrine changes in chronic cardiac failure. Basic Res Cardiol (1996) 0.76
B-type natriuretic peptide: beyond a diagnostic. Heart Fail Clin (2008) 0.75
Designer natriuretic peptides. J Clin Invest (1993) 0.75
The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med (1992) 3.53
Atrial natriuretic peptide elevation in congestive heart failure in the human. Science (1986) 3.37
Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet (1993) 3.34
Modulation of vascular smooth muscle contraction by the endothelium. Annu Rev Physiol (1986) 2.76
Respiratory epithelium inhibits bronchial smooth muscle tone. J Appl Physiol (1985) (1985) 2.45
Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension (1996) 2.37
KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric (2005) 2.32
Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med (1991) 2.22
Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation (1998) 2.08
Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res (1993) 1.98
Atrial natriuretic peptide and blood pressure in a population-based sample. Mayo Clin Proc (1995) 1.98
Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke (2000) 1.83
Natriuretic peptide system in human heart failure. Circulation (1993) 1.79
Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol (1984) 1.71
Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc (1992) 1.70
Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart (2009) 1.69
The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med (1998) 1.60
Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res (1988) 1.58
Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther (1988) 1.57
Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest (1989) 1.57
Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation (1990) 1.57
Endothelin in human congestive heart failure. Circulation (1994) 1.56
Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation (1995) 1.55
Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol (1990) 1.55
Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. Mayo Clin Proc (1998) 1.53
Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest (1988) 1.53
In vitro evaluation of endothelial and smooth muscle function of primary varicose veins. J Vasc Surg (1992) 1.51
Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol (1992) 1.50
Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. Am J Physiol Heart Circ Physiol (2001) 1.44
Expression of atrial natriuretic factor in the human ventricle is independent of chamber dilation. J Am Coll Cardiol (1990) 1.41
Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol (1992) 1.41
Endothelial alpha 2-adrenoceptors in canine pulmonary and systemic blood vessels. Eur J Pharmacol (1985) 1.33
Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol (1998) 1.32
Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol (1980) 1.31
Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc (2001) 1.29
Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol (2000) 1.28
Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res (1987) 1.27
Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol (1992) 1.27
Adenylate kinase-catalyzed phosphotransfer in the myocardium : increased contribution in heart failure. Circ Res (1999) 1.24
Failing energetics in failing hearts. Curr Cardiol Rep (2000) 1.24
Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol (1992) 1.23
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23
Adrenomedullin: potential in physiology and pathophysiology. Life Sci (2000) 1.22
The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians (1999) 1.20
C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol (1993) 1.19
Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation (1995) 1.18
Heterogeneity of endothelium-dependent responses in mammalian blood vessels. J Cardiovasc Pharmacol (1985) 1.16
Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int (1996) 1.15
Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens (2000) 1.12
Modulation of endothelium-dependent responses by chronic alterations of blood flow. Am J Physiol (1986) 1.09
A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J (1999) 1.09
Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail (2000) 1.07
Spatial correlates of hippocampal unit activity are altered by lesions of the fornix and endorhinal cortex. Brain Res (1980) 1.07
Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep (2000) 1.06
Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension (2001) 1.05
Intact and altered endothelium in regulation of vasomotion. Circulation (1992) 1.05
Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int (1999) 1.05
Alpha 2-adrenoceptors and endothelium-derived relaxing factor. Am J Med (1989) 1.04
Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase. Am J Physiol (1985) 1.04
Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries. Am J Physiol (1992) 1.04
Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation (1993) 1.03
C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol (1998) 1.03
Risks for renal dysfunction with cardiac angiography. Ann Intern Med (1986) 1.03
Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol (2000) 1.02
Does endothelin-1 mediate endothelium-dependent contractions during anoxia? J Cardiovasc Pharmacol (1989) 1.02
A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest (1995) 1.02
Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol (1997) 1.02
Cardiovascular, renal, and endocrine response to atrial natriuretic peptide in angiotensin II mediated hypertension. Circ Res (1986) 1.01
Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc (1991) 1.01
Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol (1995) 0.99
Vascular effects of estrogens: arterial protection versus venous thrombotic risk. Trends Endocrinol Metab (2001) 0.98
Circulating microparticles and endogenous estrogen in newly menopausal women. Climacteric (2009) 0.98
Endothelin has biological actions at pathophysiological concentrations. Circulation (1991) 0.97
Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. Eur J Pharmacol (1989) 0.97
Segmental analysis of sodium reabsorption during renal vein constriction. Am J Physiol (1982) 0.97
Nitric oxide as a mediator of nucleus pulposus-induced effects on spinal nerve roots. J Orthop Res (2000) 0.97
Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest (1993) 0.97
ANP inhibits Na(+)-H+ antiport in proximal tubular brush border membrane: role of dopamine. Kidney Int (1990) 0.97
Early remodeling of saphenous vein grafts: proliferation, migration and apoptosis of adventitial and medial cells occur simultaneously with changes in graft diameter and blood flow. J Vasc Res (2001) 0.96
Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol (2000) 0.96
The relationship between atrial granularity and circulating atrial natriuretic peptide in hamsters with congestive heart failure. Mayo Clin Proc (1986) 0.96
Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway. Kidney Int (1997) 0.95
Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol (1998) 0.95
Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med (1987) 0.95
Reduced activity of enzymes coupling ATP-generating with ATP-consuming processes in the failing myocardium. Mol Cell Biochem (1999) 0.95
Cardio-renal-endocrine dynamics during stepwise infusion of physiologic and pharmacologic concentrations of atrial natriuretic factor in the dog. Circ Res (1987) 0.95
Increased endothelin in experimental heart failure. Circulation (1990) 0.94
Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation (1999) 0.94
Endothelin: a new cardiovascular regulatory peptide. Mayo Clin Proc (1990) 0.94
Renal localization and actions of adrenomedullin: a natriuretic peptide. Am J Physiol (1995) 0.93
Cardiac atrial natriuretic factor during evolution of congestive heart failure. Am J Physiol (1992) 0.93
Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun (1994) 0.93
High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector. Protein Sci (2001) 0.93